1002 related articles for article (PubMed ID: 32334337)
1. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
Maillet D; Corbaux P; Stelmes JJ; Dalle S; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Freyer G; Boespflug A; Péron J
Eur J Cancer; 2020 Jun; 132():61-70. PubMed ID: 32334337
[TBL] [Abstract][Full Text] [Related]
2. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.
Corbaux P; Maillet D; Boespflug A; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Dalle S; Falandry C; Péron J
Eur J Cancer; 2019 Nov; 121():192-201. PubMed ID: 31590080
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
4. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
5. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
6. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
7. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
Nigro O; Pinotti G; De Galitiis F; Di Pietro FR; Giusti R; Filetti M; Bersanelli M; Lazzarin A; Bordi P; Catino A; Pizzutilo P; Galetta D; Marchetti P; Botticelli A; Scagnoli S; Russano M; Santini D; Torniai M; Berardi R; Ricciuti B; De Giglio A; Chiari R; Russo A; Adamo V; Tudini M; Silva RR; Bolzacchini E; Giordano M; Di Marino P; De Tursi M; Rijavec E; Ghidini M; Vallini I; Stucci LS; Tucci M; Pala L; Conforti F; Queirolo P; Tanda E; Spagnolo F; Cecchi F; Bracarda S; Macrini S; Santoni M; Battelli N; Fargnoli MC; Porzio G; Tuzi A; Suter MB; Ficorella C; Cortellini A
Eur J Cancer; 2020 Jul; 134():19-28. PubMed ID: 32454395
[TBL] [Abstract][Full Text] [Related]
8. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
9. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Naqash AR; Ricciuti B; Owen DH; Florou V; Toi Y; Cherry C; Hafiz M; De Giglio A; Muzaffar M; Patel SH; Sugawara S; Burkart J; Park W; Chiari R; Sugisaka J; Otterson GA; de Lima Lopes G; Walker PR
Cancer Immunol Immunother; 2020 Jul; 69(7):1177-1187. PubMed ID: 32140762
[TBL] [Abstract][Full Text] [Related]
10. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
11. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; Santoni M; Tudini M; Ghidini M; Filetti M; Catino A; Pizzutilo P; Sala L; Occhipinti MA; Citarella F; Russano M; Torniai M; Cantini L; Follador A; Sforza V; Nigro O; Ferrara MG; D'Argento E; Leonetti A; Pettoruti L; Antonuzzo L; Scodes S; Landi L; Guaitoli G; Baldessari C; Bertolini F; Della Gravara L; Dal Bello MG; Belderbos RA; De Filippis M; Cecchi C; Ricciardi S; Donisi C; De Toma A; Proto C; Addeo A; Cantale O; Ricciuti B; Genova C; Morabito A; Santini D; Ficorella C; Cannita K
Clin Lung Cancer; 2020 Nov; 21(6):498-508.e2. PubMed ID: 32680806
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
[TBL] [Abstract][Full Text] [Related]
13. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
14. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
[TBL] [Abstract][Full Text] [Related]
16. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
17. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
Baldini C; Martin Romano P; Voisin AL; Danlos FX; Champiat S; Laghouati S; Kfoury M; Vincent H; Postel-Vinay S; Varga A; Vuagnat P; Ribrag V; Mezquita L; Besse B; Hollebecque A; Lambotte O; Michot JM; Soria JC; Massard C; Marabelle A
Eur J Cancer; 2020 Apr; 129():71-79. PubMed ID: 32143106
[TBL] [Abstract][Full Text] [Related]
18. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
